logo-loader
viewCollagen Solutions PLC

Collagen Solutions assesses last patient in ChondroMimetic trial

Jamal Rushdy, chief executive of Collagen Solutions PLC (LON:COS) tells Proactive they're now putting together the results of a retrospective, eight-year study of its ‘scaffold’ product that helps fix cartilage defects in the knee.

The 15 patients whose results are being analysed took part in a 2009/10 trial.

Quick facts: Collagen Solutions PLC

Price: 2.95 GBX

LSE:COS
Market: LSE
Market Cap: £13.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Collagen Solutions PLC named herein, including the promotion by the Company of Collagen Solutions PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: Yo-yoing FTSE 100 heads lower again, Whitbread sees subdued...

Headlines from the Proactive UK newsroom. The FTSE 100 retreated on mild profit taking after yesterday’s big gains and a pause for breath by Asian markets. The blue chip index shed 60 to 6,225. JD Sports Fashion PLC(LON:JD.) is to beef up its main warehouse, near Manchester, as it expects...

6 days, 5 hours ago

2 min read